On a veterinary parenteral manufacturing line, the acceptance of a Shuanghuanglian for Injection Veterinary Grade API batch for sterile aqueous injection is contingent on cold-water solubility, bacterial endotoxin load, and the HPLC peak-area ratio of chlorogenic acid to baicalin, because these three parameters determine whether the compounded solution can be processed through sterilizing filtration without membrane blinding and whether the final vial can be released against the pyrogen specification for intramuscular administration in pigs. The compounding suite operates under EU GMP Annex 1: Manufacture of Sterile Medicinal Products (2022 revision), with filling performed in ISO 14644-1:2015 ISO 5 conditions and solution preparation in ISO 7. Terminal release includes sterility testing according to Ph. Eur. 2.6.1 or USP <71>, and bacterial endotoxin testing according to Ph. Eur. 2.6.14 or USP <85>. Residual solvent control follows VICH GL18/ICH Q3C limits, and marker assay is performed against reference substances defined in the Chinese Veterinary Pharmacopoeia (2020 Edition) Shuanghuanglian injection monograph where applicable.

Formulation addition ratio for terminal aqueous injection is normally set at 0.4 g–0.6 g standardized dry extract per 10 mL finished solution, adjusted to the approved dose per kilogram body weight for the target species. The extract is dissolved in Water for Injection at 45 ± 5 °C under nitrogen purge because sustained compounding temperatures above 60 °C accelerate chlorogenic acid hydrolysis and increase the area of late-eluting oxidative peaks in the HPLC fingerprint. The solution is cooled to 20–25 °C, pH-adjusted within the registered range, and treated with 0.1% w/v activated carbon for decolorization if the batch shows elevated color units. A depth filter with nominal retention of 0.6–0.8 µm is then used to remove carbon fines and aggregated polyphenols; without this pre-filter, the final 0.22 µm polyethersulfone membrane can blind after only 200–400 L/m², causing line stoppage. The pre-filtration bioburden limit is held at ≤ 10 CFU/100 mL before the sterilizing filter. Finished product is filled into Type I glass vials under nitrogen and closed with bromobutyl stoppers. Aseptic filling is the default when stability data show chlorogenic acid loss above 5% after terminal steam sterilization at 121 °C for 15 min; otherwise terminal sterilization may be applied if the registered formulation includes an oxygen scavenger or pH buffer that stabilizes the phenolic marker. The portfolio covers 10 mL, 20 mL, and 50 mL single-dose and multi-dose vials.

Material compatibility is restricted to 316L stainless steel, PTFE, and pharmaceutical-grade silicone; carbon steel fittings are excluded because polyphenolic fractions leach iron and form dark complexes. Process water for injection is monitored for heavy metals by atomic absorption before compounding; iron content above 0.1 ppm or copper above 0.05 ppm triggers a water-loop investigation. The holding time between final filtration and start of filling is limited to ≤ 4 h at 2–8 °C; beyond this window, bioburden recovery and pH drift invalidate the batch unless a validated hold-time study shows otherwise.

Why Does High Feed-Water Hardness Precipitate Baicalin in Oral Solution Lines?

When regional drinking-water hardness exceeds 120 mg/L CaCO₃ equivalent, divalent cations interact with the glucuronide moiety of baicalin and produce poorly soluble metal complexes that settle as a yellow-brown deposit in oral solution tanks and volumetric dosing pumps. Manufacturing for oral solutions therefore begins with softened or deionized water, and the formulation addition ratio for Shuanghuanglian extract is maintained between 2.0% w/v and 5.0% w/v, depending on the marker content of the incoming API batch. The compounding process follows non-sterile liquid GMP conditions; microbial quality of the finished oral solution is controlled according to Ph. Eur. 5.1.4 or USP <61>/USP <62> with specified limits for total aerobic microbial count and absence of Escherichia coli in 1 mL. In the Chinese Veterinary Pharmacopoeia (2020 Edition) oral solution monograph, assay limits for chlorogenic acid and baicalin define the release window that the import dossier must meet.

Processing begins in a jacketed stainless-steel vessel at 35–40 °C. The extract is pre-dissolved in a 10% w/v concentrate at pH 5.0–5.5 with citrate buffer, then diluted into the main batch. Sodium metabisulfite at 0.05% w/v is used only where the stability protocol demonstrates no sulfite sensitivity in the target species. The liquid is clarified through a 1 µm polypropylene cartridge and transferred to a vacuum deaeration unit to remove foam that otherwise causes volume discrepancy during automatic filling. Hardness is monitored at the water inlet to the compounding vessel; if conductivity rises above 10 µS/cm or total hardness exceeds 15 mg/L CaCO₃, the production line switches to a reserve water source because the resulting precipitate is not removable by routine filtration and would require line disassembly. Terminal products are filled into 100 mL, 500 mL, and 1 L HDPE bottles with induction-sealed closures.

In drinking-water medication for broilers, the flow properties and particle size distribution of the Shuanghuanglian extract dictate whether the final soluble powder dissolves completely at a 1:1000 dilution within 60 s under field conditions, because undissolved particles bind to nipple drinkers and create uneven intake across a poultry house. The finished powder is formulated with 10% w/w to 20% w/w standardized extract on a dextrose/lactose carrier, with the exact ratio set by the marker assay of the API batch so that 1 g of finished powder delivers the approved mg/kg-day dose when added to the daily water volume per thousand birds. The API is pre-milled in a pin mill with jacket temperature not exceeding 35 °C to a particle size of D90 ≤ 75 µm; over-milling increases hygroscopic surface area and causes clumping during storage. Blending is performed in a stainless-steel ribbon mixer at 60% fill volume for 15 min at 20 rpm, followed by addition of 0.5% w/w colloidal silicon dioxide as anticaking agent and a second short blend of 5 min. The blend is discharged only when moisture content is ≤ 5.0% and tapped bulk density deviates less than 5% from the setting established during process validation.

Compliance release includes absence of Salmonella in 25 g, total aerobic microbial count and total combined yeasts/moulds count according to Ph. Eur. 5.1.4 or USP <61>/USP <62>, and HPLC content uniformity for three marker compounds: chlorogenic acid, baicalin, and forsythoside A. Packaging operations are conducted at relative humidity ≤ 30% RH because the extract is deliquescent above 55% RH; foil laminate sachets of 100 g, 500 g, and 1 kg are sealed immediately after filling, and oxygen absorbers are inserted when the export container exceeds 60% RH during maritime transit. The production-scale bottleneck is the shift-cleaning step: residual extract film on the ribbon mixer must be removed with dry vacuum followed by 70% isopropanol wipe-down, because water washing without complete drying accelerates microbial growth in corners and paddle welds.

Binder Viscosity Below 120 mPa·s Prevents Granule Case Hardening in Shuanghuanglian Feed Top-Dressing Agents

Granule case hardening is observed when the aqueous binder viscosity in a high-shear granulation process exceeds 120 mPa·s at 25 °C, creating a dense surface film that slows subsequent wetting and dosing in swine feed top-dressing applications. Shuanghuanglian extract is incorporated into granules at 5% w/w to 10% w/w of total granulation mass, premixed with microcrystalline cellulose and native corn starch in a planetary mixer before transfer to a high-shear granulator. The granulation end point is controlled by impeller torque rather than time; at 120 rpm impeller speed and 1,500 rpm chopper speed, the target torque window is 6–8 A on the drive motor for a 50 kg bowl. Binder solution is PVP K30 at 5% w/v, sprayed at 0.5 L/min through a top-spray lance; viscosity is checked before spraying because higher solids content raises viscosity and promotes case hardening after fluid-bed drying. The wet mass is discharged through an 8 mm screen and dried in a fluid-bed dryer with inlet air 60 °C and product temperature 35–40 °C until loss on drying ≤ 2.5%. Dried granules are sized between 20 mesh and 40 mesh; oversize granules are milled through a low-shear cone mill, not a hammer mill, to preserve the porous structure required for rapid resuspension in feed.

Compliance for this dosage form is anchored to non-sterile veterinary granule GMP and the Chinese Veterinary Pharmacopoeia (2020 Edition) granule monograph, with moisture by loss on drying and content uniformity tested according to USP <905> or equivalent. Stability testing follows the bracketing design described in VICH GL1 for zones where the export climate profile reaches 30 °C/75% RH; the primary failure mode in accelerated stability is not marker loss but moisture ingress above 3.0%, which degrades flow and causes clumping in the final foil pouch. Terminal packaging uses 50 g, 100 g, and 500 g heat-sealed foil-laminate pouches with a desiccant sachet when closure integrity testing indicates a moisture vapor transmission rate above 0.5 g/m²/day.

Carryover Control and Stepwise Dilution in Shuanghuanglian Medicated Premix Lines

Medicated premix production for Shuanghuanglian extract is governed by EU 2019/4 on medicated feed, which imposes a validated maximum carryover limit and requires that the active substance be incorporated into a homogeneous premix before final feed addition. The addition ratio in the finished premix is calculated on crude herb equivalent, typically 500 g to 2,000 g API per 1,000 kg complete feed, with the premix itself prepared as a 1:100 intermediate. Stepwise dilution in two stages is mandatory because direct addition of the fine API into the final mixer produces electrostatic segregation and drug concentration variability above 10% relative standard deviation. First-stage blending combines the API with rice hull or microcrystalline cellulose at 1:10 in a double-cone blender for 10 min at 70% fill volume; second-stage blending dilutes the intermediate with ground corn or wheat middlings to the final premix. The coefficient of variation for the active marker in the final mixer must be ≤ 5% across 10 sampling points, as specified by the operator’s validated protocol under EU 2019/4. After each batch, the line is flushed with 50 kg ground corn and the flush is disposed of or used only in the same target species if carryover validation demonstrates marker content below the established limit.

Release testing for the premix includes HPLC determination of baicalin and chlorogenic acid in a sample prepared by quartering, with the acceptance window fixed by the marketing authorization dossier. Because the extract is hygroscopic, the premix moisture content is held below 5.0%; above this threshold the material compacts in screw conveyors and produces lumps that do not disperse in feed. Packaging uses 1 kg, 5 kg, and 25 kg multi-wall paper bags with a 0.05 mm low-density polyethylene liner, and palletized loads are stretch-wrapped only after the product temperature has equilibrated to 20–25 °C. The critical environmental control is relative humidity in the blending room, which must not exceed 35% RH during open handling; otherwise moisture uptake alters the flow function and shifts the mixer discharge rate, leading to underfilled bags on high-speed packaging lines.

When Tablet Compaction Replaces Soluble Powder for Companion Animal Oral Bolus Administration

Tablet compression is selected over soluble powder when the veterinary prescriber requires a fixed oral bolus for companion animals or small ruminants, and this route demands a formulation that balances the hygroscopic Shuanghuanglian extract with direct-compression fillers to avoid punch sticking. The core blend comprises 20% w/w to 30% w/w standardized extract, 40% w/w microcrystalline cellulose PH102, 20% w/w lactose monohydrate, 3% w/w croscarmellose sodium, and 1% w/w magnesium stearate; the extract is granulated before compression because direct compression of the as-received powder produces capping at compression forces above 8 kN. Wet granulation uses a 70:30 ethanol-water solvent system, tray drying at 50 °C until loss on drying ≤ 2.0%, and dry screening through a 16-mesh screen. Compression is performed on a rotary press at 20–30 rpm with pre-compression force 2–3 kN and main compression 8–12 kN; tablet hardness is maintained at 60–90 N and friability is controlled to ≤ 1.0%. The immediate-release core is coated with hydroxypropyl methylcellulose film to isolate the extract from atmospheric moisture, because at 55% RH uncoated tablets gain more than 2% moisture within 24 h and develop brown surface mottling.

Compliance release uses disintegration testing according to USP <701>/Ph. Eur. 2.9.1, content uniformity according to USP <905>, and dissolution testing where the registered species-specific monograph requires it. Published data for the dissolution kinetics of Shuanghuanglian tablets in feline or canine gastric fluid is limited; the dissolution method is therefore justified by the manufacturer through pre-validation in media at pH 1.2 and pH 4.5 with paddle speed 50 rpm. The finished oral bolus forms are 250 mg and 500 mg tablets, and the same granulated intermediate can be filled into size 0 capsules at 250 mg fill weight when a capsule presentation is required by the importer. Capsule filling is conducted at ≤ 30% RH because the granulate absorbs moisture during hopper residence and then produces variable fill weights on tamping-pin machines; the manufacturing dry room therefore uses desiccant dehumidification rather than cooling-based systems, because the latter cannot achieve the required dew point of ≤ 5 °C during wet-season runs in tropical export locations.